Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nicomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 10/20 | 0.68 |
| ▸ | OPRM1 known ✓ | P35372 | 12/20 | 0.59 |
| ▸ | OPRK1 known ✓ | P41145 | 10/20 | 0.59 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.53 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.53 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicomorphine SCHEMBL680036 | 0.99 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL29408441 | 0.99 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL29349768 | 0.99 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL26237 | 0.99 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL1649977 | 0.98 | OPRD1 (0.68) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL1023092 | 0.93 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL159020 | 0.93 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL29531263 | 0.93 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| SCHEMBL27496008 | 0.90 | OPRD1 (0.66) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| SCHEMBL1556900 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1OPRK1ADRB1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272508-B1 | Pharmaceutical formulations for dry powder inhalers | VECTURA LTD (GB) | 2020-03-25 | — | — | EP | disclosed |
| US-10561613-B2 | Method of making particles for use in a pharmaceutical composition | VECTURA LIMITED (GB) | 2020-02-18 | — | — | US | disclosed |
| EP-2266549-B1 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | VECTURA LTD (GB) | 2019-08-07 | — | — | EP | disclosed |
| EP-1296651-B2 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | VECTURA LTD (GB) | 2019-07-17 | — | — | EP | disclosed |
| US-20180318170-A1 | Inhalable Pharmaceutical Compositions | ICEUTICA PTY LTD. (AU) | 2018-11-08 | — | — | US | disclosed |
| US-10022303-B2 | Inhalable pharmaceutical compositions | ICEUTICA PTY LTD. (AU) | 2018-07-17 | — | — | US | disclosed |
| US-20180055772-A1 | Method Of Making Particles For Use In A Pharmaceutical Composition | VECTURA LTD (GB) | 2018-03-01 | — | — | US | disclosed |
| EP-1913939-B1 | Formulations for use in inhaler devices | VECTURA LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9566239-B2 | Pharmaceutical formulations for dry powder inhalers | VECTURA LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
| US-20160243039-A1 | Method Of Making Particles For Use In A Pharmaceutical Composition | VECTURA LTD (GB) | 2016-08-25 | — | — | US | disclosed |
| EP-1296651-A1 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | Vectura Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| EP-1278516-A1 | POWDERS FOR USE IN A DRY POWDER INHALER | Vectura Limited (GB) | 2003-01-29 | — | — | EP | disclosed |
| EP-1276472-A2 | FORMULATIONS FOR USE IN INHALER DEVICES | Vectura Limited (GB) | 2003-01-22 | — | — | EP | disclosed |
| EP-1276474-A2 | FORMULATIONS FOR USE IN INHALER DEVICES | Vectura Limited (GB) | 2003-01-22 | — | — | EP | disclosed |
| EP-1276473-A2 | PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS | Vectura Limited (GB) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002000197-A1 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | VECTURA LIMITED (GB) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001082906-A1 | POWDERS FOR USE IN A DRY POWDER INHALER | VECTURA LIMITED (GB) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001078696-A2 | FORMULATIONS FOR USE IN INHALER DEVICES | VECTURA LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078695-A2 | PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS | VECTURA LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078694-A2 | FORMULATIONS FOR USE IN INHALER DEVICES | VECTURA LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |